TD2 to Present at the Upcoming 4th Annual Tumor Models in Boston

July 15, 2016

TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th.  The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.

Contact us if you’re interested in a copy of the presentation.

The Importance of Conducting PDX Oncology Studies in a Humanized Immune System

Preclinical oncology studies are a critical step in developing effective cancer therapies. Patient-derived xenograft (PDX) models have become a ...

Read more +

Leveraging Flow Cytometry to Drive Better Patient Outcomes in Hematologic Malignancy Clinical Trials

In oncology, evaluating treatment efficacy often relies on standardized criteria such as RECIST (Response Evaluation Criteria in Solid Tumors), which ...

Read more +

The Importance of Incorporating Metabolomic and Proteomic Screening in Preclinical Oncology Studies

The evolving complexity of oncology drug development demands an equally sophisticated approach to understanding the tumor microenvironment and its ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.